

**Health Technology Clinical Committee
Findings and Decision**

Topic: Tumor treating fields, (TTF) – re-review

Meeting date: November 16, 2018

Final adoption: January 18, 2019

Meeting materials and transcript are available on the [HTA website](#).

Number and coverage topic:

20181116A - Tumor treating fields, (TTF) – re-review

HTCC coverage determination:

Tumor treating fields is **not a covered benefit**.

HTCC reimbursement determination:

Limitations of coverage:

N/A

Non-covered indicators:

N/A

Agency contact information:

Agency	Phone Number
Labor and Industries	1-800-547-8367
Public Employees Health Plan	1-800-200-1004
Washington State Medicaid	1-800-562-3022

Final

HTCC coverage vote and formal action:

Committee decision

Based on the deliberations of key health outcomes the committee decided that it had the most complete information: a comprehensive and current evidence report, public comments, and state agency utilization information. The committee decided that the current evidence on tumor treating fields, (TTF) is sufficient to make a determination on this topic. The committee discussed and voted on the evidence for the use of TTF for: 1) newly diagnosed glioblastoma multiforme; 2) recurrent glioblastoma multiforme; and 3) treatment of other cancers. The committee considered the evidence and gave greatest weight to the evidence it determined, based on objective factors, to be the most valid and reliable.

Based on these findings, the committee voted to not cover tumor treating fields for treatment of newly diagnosed glioblastoma multiforme, recurrent glioblastoma multiforme, and for treatment of other cancers.

	Not covered	Covered under certain conditions	Covered unconditionally
Tumor treating fields – newly diagnosed	9	0	0
Tumor treating fields - recurrence	9	0	0
Tumor treating fields – other cancers	9	0	0

Discussion

The committee reviewed and discussed the available studies for use of TTF. Details of study design, inclusion criteria, outcomes and other factors affecting study quality were discussed. A majority of committee members found the evidence sufficient to determine that use of TTF was equivalent for safety unproven for efficacy and less cost-effective than comparators.

Limitations

N/A

Action

The committee checked for availability of a Centers for Medicare and Medicaid Services (CMS) national coverage decision (NCD). There is no NCD for tumor treating fields.

The committee discussed clinical guidelines identified for tumor treating fields from the following organizations:

- National Comprehensive Cancer Network (NCCN) – 2018
NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers Version 1.2018
- U.K. National Institute for Health and Care Excellence (NICE) – 2018
Brain tumours (primary) and brain metastases in adults (2018)

Final

- Medical Oncology Spanish Society (SEOM) – 2017
SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017)
- European Association for Neuro-Oncology (EANO) – 2017
EANO guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas (2017)
- America Association of Neuroscience Nurses (AANN) 2016
Care of the Adult Patient with a Brain Tumor (2014)39 (Revised 2016)
- European Society of Medical Oncology (ESMO) 2014
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up (2014)

The committee determined the guidelines do not have concordant recommendations. The HTCC determination is consistent with some and differs from some of the reviewed guidelines.

The committee chair directed HTA staff to prepare a findings and decision document on use of tumor treating fields for public comment; followed by consideration for final approval at the next public meeting.

Health Technology Clinical Committee Authority:

Washington State's legislature believes it is important to use a science-based, clinician-centered approach for difficult and important health care benefit decisions. Pursuant to chapter 70.14 RCW, the legislature has directed the Washington State Health Care Authority (HCA), through its Health Technology Assessment (HTA) program, to engage in an evaluation process that gathers and assesses the quality of the latest medical evidence using a scientific research company and that takes public input at all stages.

Pursuant to RCW 70.14.110 a Health Technology Clinical Committee (HTCC) composed of eleven independent health care professionals reviews all the information and renders a decision at an open public meeting. The Washington State HTCC determines how selected health technologies are covered by several state agencies (RCW 70.14.080-140). These technologies may include medical or surgical devices and procedures, medical equipment, and diagnostic tests. HTCC bases its decisions on evidence of the technology's safety, efficacy, and cost effectiveness. Participating state agencies are required to comply with the decisions of the HTCC. HTCC decisions may be re-reviewed at the determination of the HCA Director.

Final